Now Reading
Type 1 Diabetes: What you need to know about this lifelong condition

Type 1 Diabetes: What you need to know about this lifelong condition

All about Type 1 Diabetes, its management and the Evolution of Treatment options available.

Dr Luqman Ibrahim,
Consultant Endocrinologist

November is World Diabetes Awareness Month, commemorating the birthday of Dr Frederick Banting, who discovered insulin about 100 years ago in Toronto, Canada, alongside Charles H Best and JJR Macleod(1). Since then, diabetes has been recognised as a pandemic, with a rapid increase, especially in developing countries, as they shift to more modern economies.

According to the World Health Organisation, diabetes claims about three lives every minute worldwide 1 and affects over 1 in 5 Malaysians; however, The Malaysian Diabetes Index revealed that there is still a lack of understanding about diabetes and its various health complications(2).

Looking At Diabetes With A Magnifying Glass

There are two common types of diabetes, known as Type 1 and Type 2 diabetes, that occur when the pancreas does not produce sufficient insulin. Insulin is a hormone that moves blood sugar into cells to have energy. Type 2 diabetes generally occurs during adulthood and is associated with multiple factors, including genetic, hormonal, environmental, lifestyle, and other medical conditions. On the other hand, Type 1 diabetes is less commonly known and generally affects children and young adults.

Type 1 diabetes is an autoimmune condition where a person produces abnormal antibodies that attack their normal cells and tissues. In the case of people with Type 1 diabetes, these antibodies attack and damage specifically the insulin-producing cells in the pancreas, also known as the beta cells. Type 1 diabetes affects over 9 million people worldwide, including Nick Jonas, Halle Berry and Theresa May.

Once the beta cells are completely damaged, the person will experience high glucose (hyperglycaemia) and eventually a life-threatening condition called diabetic ketoacidosis (DKA).

Why is Diabetic Ketoacidosis (DKA) Life Threatening?

Diabetic ketoacidosis (DKA) is a medical emergency caused by very high glucose and the accumulation of ketone bodies in the blood. When people do not have enough insulin, they cannot utilise it as the primary source. In response, the body breaks down fat tissues and releases ketone bodies in excessive amounts(3). Once too many ketone bodies are in the blood, it causes the blood to become too acidic(4), leading to multiple organ failures, including heart failure and coma.

The main symptoms of Type 1 diabetes include unexplained weight loss, increased urination at night, and excessive lethargy. When a person or a child develops DKA, they will also experience abdominal pain, vomiting, breathing difficulties, and eventually, lose consciousness if not promptly treated.

How is Type 1 Diabetes Diagnosed?

Once a person experiences the symptoms of Type 1 diabetes but does not receive the correct diagnosis and treatment, they may progress to develop DKA within 2 to 4 weeks. However, given this rapid progression of symptoms, most children and adults with Type 1 diabetes are diagnosed only at a later stage, when they have already developed DKA.

The diagnosis of Type 1 diabetes can be made by demonstrating high blood glucose in people with the typical symptoms in the absence of other features to suggest different types of diabetes, for example, obesity, older age, and pregnancy.

The confirmation of Type 1 diabetes diagnosis can be made by measuring the antibodies specific to the beta cells. Still, the test results are only received after a few weeks. However, treatment for Type 1 diabetes should be started immediately when the blood glucose is found to be elevated to avoid DKA, without waiting for these antibody test results.

How is Type 1 Diabetes treated?

All patients with Type 1 diabetes require insulin treatment for the rest of their lives. Otherwise, they will relapse back into DKA. However, insulin treatment in people with Type 1 diabetes can be complex and requires continuous learning.

Studies have also shown that despite insulin treatment, people with Type 1 diabetes can still develop long-term diabetes complications such as kidney failure, blindness, amputations, and cardiovascular diseases. These complications can be prevented by aiming for lower HbA1c (average blood sugar levels over the last two to three months) with intensive insulin treatment(5).

Patients with Type 1 diabetes are also prone to experience low blood glucose (hypoglycaemia) from insulin treatment. To achieve the target HbA1c and minimise the risk of hypoglycaemia, such intensive insulin treatment often involves multiple daily insulin injections, frequent blood glucose monitoring by finger pricking, carbohydrate counting, and matching insulin doses to carbohydrate intakes. Acquiring these skills and self-managing Type 1 diabetes daily requires continuous learning and communicating regularly with the diabetes care providers.

Technological Advancements in Diabetes Management However, new technologies have been developed to make self-management of Type 1 diabetes more manageable. This includes treatment options such as:

  1. A continuous glucose monitoring (CGM) system is designed to track glucose levels using a sensor placed on the skin that automatically tracks glucose levels throughout the day. It lets patients see their results in real-time without pricking their fingers through a mobile app or a handheld device(6). It has been used by people with Type 1 diabetes with encouraging results.
  2. Insulin pumps are small, computerised devices that deliver a continuous insulin infusion into the skin without requiring multiple injections. These devices can be programmed to deliver customised rates of insulin at different times of the day and for different amounts of carbohydrate intakes, especially when eating larger volumes(7).
  3. Closed-loop system technology (Artificial pancreas) combines the best CGM systems and insulin pumps to create an automated insulin delivery system based on the monitored continuous glucose data. These closed-loop systems are often also called the “artificial pancreas”, although they still have some limitations as compared to the average human pancreas(8).

Can Type 1 Diabetes be cured?

While there is still no cure for Type 1 diabetes, islet cell transplantation containing beta cells has been used for remission for patients with Type 1 diabetes; however, this remission is often short-lived(9). However, as new treatments, including fully automated insulin delivery systems and stem-cell-derived beta cells, are being developed, we can expect to see new treatment possibilities that will improve the lives of people with Type 1 diabetes (10).

In summary, Type 1 diabetes is an uncommon, complex condition that requires a lifelong learning process and a team of experienced diabetes care providers for the best treatment outcome. Hence it is essential for people with Type 1 diabetes to have access to these diabetes care providers who can provide multidisciplinary care to address their complex needs.

Dr Luqman is based at the Diabetes Care Unit at Regency Specialist Hospital. He works with a multidisciplinary team of experts that provides specialist consultation, diabetes education with a pharmacist and dietician, consultation with psychologists or psychiatrists, and even access to support groups needed to manage diabetes.


  1. World Health Organisation. (2021, November). Diabetes Fact Sheet.
  5. Nakashima, K., Okamura, N., Sanefuji, H. et al. Practical application of short-term intensive insulin therapy based on the concept of “treat to target” to reduce hypoglycaemia in routine clinical site. Sci Rep 10, 1552 (2020).
  8. Ministry of Health (2016), Artificial Pancreas For Type 1 Diabetes Mellitus, Report No: 007/2016
  9. Diabetes UK. (2010, October). Commissioning Specialist Diabetes Services for Adults with Diabetes , A Diabetes UK Task and Finish Group Report.
  10. Ministry of Health (2016), Artificial Pancreas For Type 1 Diabetes Mellitus, Report No: 007/2016
  11. Srinivasan P, Huang GC, Amiel SA, Heaton ND. Islet cell transplantation. Postgrad Med J. 2007 Apr;83(978):224-9. doi: 10.1136/pgmj.2006.053447. PMID:17403947; PMCID: PMC2600029.
  12. Latres E, Finan DA, Greenstein JL, Kowalski A, Kieffer TJ. Navigating Two Roads to Glucose Normalization in Diabetes: Automated Insulin Delivery Devices and Cell Therapy. Cell Metab. 2019 Mar 5;29(3):545-563. doi: 10.1016/j.cmet.2019.02.007. PMID: 30840911.
  13. Louis Rosenfeld, Insulin: Discovery and Controversy, Clinical Chemistry, Volume 48, Issue 12, 1 December 2002, Pages 2270–2288,

If you’d like to have your opinion shared on TRP, please send it via email at with the title “OPINION:” or through social media on TRP’s FacebookTwitter, and Instagram.

Get more stories like this to your inbox by signing up for our newsletter.

© 2024 The Rakyat Post. All Rights Reserved. Owned by 3rd Wave Media Sdn Bhd